HC Wainwright Weighs in on Pharvaris FY2030 Earnings

Pharvaris N.V. (NASDAQ:PHVS) – Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Pharvaris in a note issued to investors on Monday, April 6th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $5.37 for the year. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada reduced their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.60.

Pharvaris Price Performance

Shares of PHVS stock opened at $28.37 on Tuesday. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -8.42 and a beta of -2.58. Pharvaris has a one year low of $11.51 and a one year high of $29.85. The company’s fifty day moving average price is $27.07 and its 200-day moving average price is $25.47.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of PHVS. GF Fund Management CO. LTD. bought a new stake in Pharvaris in the 4th quarter valued at $35,000. JPMorgan Chase & Co. increased its holdings in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Pharvaris in the 3rd quarter valued at $75,000. Barclays PLC bought a new stake in Pharvaris in the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Pharvaris in the 4th quarter valued at $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.